Heliospectra’s report for the second quarter came in mixed with sales below our estimates but continued gross margin improvement. The company is well positioned to rapidly grow sales in all its segments with the medical plant segment and AgTech segment to take off first. A strengthened organization and intensified sales and marketing have resulted in a promising sales pipe, but also higher costs. Important catalyst going forward include legalization of recreational marijuana in California and successful launch of sensor-1 and the patented biofeedback system.